REGULATION OF PROTEIN TRAFFICKING IN ADIPOCYTES

脂肪细胞中蛋白质运输的调节

基本信息

  • 批准号:
    8032427
  • 负责人:
  • 金额:
    $ 31.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-03-01 至 2014-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The Glut4 glucose transporter catalyzes the rate-limiting step in postprandial whole body glucose disposal. A disruption in the insulin-stimulated redistribution of Glut4 to the plasma membrane is the proximal cause of the peripheral insulin resistance associated with type 2 diabetes mellitus. Elucidation of the precise molecular pathways involved in the mechanism by which insulin stimulates the acute redistribution of Glut4 to the plasma membrane may thus be of considerable importance in understanding the pathogenesis of insulin resistant states. The regulated subcellular trafficking of Glut4 is partially dictated by the insulin- responsive AS160/Rab10 GTPase cycle, but additional unidentified factors are necessary to fully account for its basal intracellular sequestration and insulin-stimulated movement to the plasma membrane. Additionally, the specific structural features of Glut4 that direct its regulated subcellular trafficking remain poorly understood. We have identified a novel subcellular targeting motif (LXXLXP) within the carboxy-terminal 12 residues of the cytoplasmic tail of Glut4 that is shared with the insulin-responsive aminopeptidase. Unlike other Glut4 targeting motifs, alteration of the LXXLXP motif (herein referred to as IRM, insulin-responsive motif) has a profound effect on the steady-state distribution of the transporter and appears to completely abolish its basal recycling and insulin-stimulated translocation to the cell surface. The goal of this proposal is to gain fundamental insights into Glut4 regulation by delineating the role of the IRM and of a putative Akt-regulated GTPase activating protein, AS250, in this process. In order to accomplish this goal, the following specific aims will be undertaken: 1) to precisely define the IRM and how it interacts with other known Glut4 targeting motifs; 2) to identify and characterize novel subcellular membrane compartments through which Glut4 moves; and 3) to elucidate the function of the AS250 complex, how insulin affects its function, and identify novel components of the AS250/KIAA1219 complex. PUBLIC HEALTH RELEVANCE: This project proposes to investigate novel aspects of how glucose transport is regulated by insulin in fat cells. It is directly relevant to understanding the molecular mechanisms involved in the regulation of whole body glucose homeostasis and its derangement in insulin resistant states such as diabetes, obesity, and metabolic syndrome.
描述(申请人提供):GLUT4葡萄糖转运体催化餐后全身葡萄糖处置的限速步骤。胰岛素刺激的GLUT4重新分布到质膜的破坏是与2型糖尿病相关的外周胰岛素抵抗的近端原因。因此,阐明胰岛素刺激GLUT4急性重分布到质膜的确切分子途径对于理解胰岛素抵抗状态的发病机制具有重要意义。GLUT4的亚细胞转运调控部分由胰岛素反应的AS160/Rab10 GTP酶周期决定,但其他未知因素是必要的,以完全解释其基本的细胞内隔离和胰岛素刺激的向质膜的移动。此外,指导其受管制的亚细胞贩运的GLUT4的具体结构特征仍然知之甚少。我们在GLUT4胞质尾部的羧基末端12个残基上发现了一个新的亚细胞靶向基序(LXXLXP),该基序与胰岛素反应性氨基肽酶共享。与其他GLUT4靶向基序不同,LXXLXP基序(这里称为IRM,胰岛素反应基序)的改变对转运蛋白的稳态分布有深远的影响,似乎完全取消了转运蛋白的基础循环和胰岛素刺激的细胞表面转位。这项建议的目标是通过描述IRM和假定的Akt调节的GTPase激活蛋白AS250在这一过程中的作用,获得对GLUT4调控的基本见解。为了实现这一目标,将采取以下具体目标:1)准确地定义IRM以及它如何与其他已知的GLUT4靶向基序相互作用;2)鉴定和表征GLUT4通过的新的亚细胞膜室;以及3)阐明AS250复合体的功能,胰岛素如何影响其功能,并确定AS250/KIAA1219复合体的新成分。 与公共健康相关:该项目建议研究胰岛素如何在脂肪细胞中调节葡萄糖运输的新方面。它直接关系到糖尿病、肥胖症和代谢综合征等胰岛素抵抗状态下糖代谢平衡调节及其紊乱的分子机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MIKE M MUECKLER其他文献

MIKE M MUECKLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MIKE M MUECKLER', 18)}}的其他基金

REGULATION OF PROTEIN TRAFFICKING IN ADIPOCYTES
脂肪细胞中蛋白质运输的调节
  • 批准号:
    8443438
  • 财政年份:
    2010
  • 资助金额:
    $ 31.22万
  • 项目类别:
REGULATION OF PROTEIN TRAFFICKING IN ADIPOCYTES
脂肪细胞中蛋白质运输的调节
  • 批准号:
    8223268
  • 财政年份:
    2010
  • 资助金额:
    $ 31.22万
  • 项目类别:
REGULATION OF PROTEIN TRAFFICKING IN ADIPOCYTES
脂肪细胞中蛋白质运输的调节
  • 批准号:
    7765902
  • 财政年份:
    2010
  • 资助金额:
    $ 31.22万
  • 项目类别:
Insulin Signaling in a Cell-Free System
无细胞系统中的胰岛素信号传导
  • 批准号:
    6919073
  • 财政年份:
    2005
  • 资助金额:
    $ 31.22万
  • 项目类别:
Insulin Signaling in a Cell-Free System
无细胞系统中的胰岛素信号传导
  • 批准号:
    7021433
  • 财政年份:
    2005
  • 资助金额:
    $ 31.22万
  • 项目类别:
Insulin Signaling in a Cell-Free System
无细胞系统中的胰岛素信号传导
  • 批准号:
    7368024
  • 财政年份:
    2005
  • 资助金额:
    $ 31.22万
  • 项目类别:
Insulin Signaling in a Cell-Free System
无细胞系统中的胰岛素信号传导
  • 批准号:
    7191655
  • 财政年份:
    2005
  • 资助金额:
    $ 31.22万
  • 项目类别:
HIV Protease Inhibitors and Glucose Transport
HIV 蛋白酶抑制剂和葡萄糖转运
  • 批准号:
    6448798
  • 财政年份:
    2002
  • 资助金额:
    $ 31.22万
  • 项目类别:
HIV Protease Inhibitors and Glucose Transport
HIV 蛋白酶抑制剂和葡萄糖转运
  • 批准号:
    6622516
  • 财政年份:
    2002
  • 资助金额:
    $ 31.22万
  • 项目类别:
HIV Protease Inhibitors & Glucose Transport
HIV蛋白酶抑制剂
  • 批准号:
    6868285
  • 财政年份:
    2002
  • 资助金额:
    $ 31.22万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.22万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.22万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 31.22万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.22万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.22万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.22万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.22万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 31.22万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 31.22万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 31.22万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了